Newsletter sign-up
Does my company subscribe?
Contact Sales:1-800-405-0844
EMARKETER
Log in
Become a ClientGet a DemoPricing
ArticlesPricing

Products

See All Solutions →
By ProductEMARKETER PRO+Analyst Access Program
By Use CaseDetermine Market SizingDevelop StrategiesAllocate BudgetBenchmark PerformanceWin New BusinessDevelop Go-to-Market StrategyStay InformedThought LeadershipSee All Use Cases →
Advertising & Sponsorship
Boost your brand and generate demand with media programs.
Learn More →

Events & Resources

Learning Center
Read through guides, explore resource hubs, and sample our coverage.
Learn More →
Events
Register for an upcoming webinar and track which industry events our analysts attend.
Learn More →
Podcasts
Listen to our podcast, Behind the Numbers for the latest news and insights.
Learn More →

Topics

See All Topics →
Advertising & MarketingSocial MediaContent MarketingEmail MarketingVideoBrowse All →
Ecommerce & RetailEcommerce SalesMcommerceRetail SalesSocial CommerceBrowse All →
Financial ServicesBankingPaymentsFintechWealth ManagementBrowse All →
GeographiesAsia-PacificCentral & Eastern EuropeLatin AmericaMiddle East & AfricaNorth AmericaWestern Europe
HealthValue-Based CareDigital TherapeuticsTelehealthOnline PharmacyBrowse All →
TechnologyConnected Devices5GArtificial Intelligence (AI)Browse All →
More IndustriesReal EstateCustomer ExperienceB2BTravelSmall Business (SMB)Browse All →

Latest Articles

Explore our Research →

Social Media Update Q2 2021

Consumer Attitudes Toward Digital Advertising 2021

Marketing with Stories 2021

Banking-as-a-Service

Digital Account Opening

Explore More Research

Browse All →

About

Our Story
Learn more about our mission and how EMARKETER came to be.
Learn More →
Our Clients
Key decision-makers share why they find EMARKETER so critical.
Learn More →
Our People
Take a look into our corporate culture and view our open roles.
Join the Team →
Our Methodology
Rigorous proprietary data vetting strips biases and produces superior insights.
Learn More →
Newsroom
See our latest press releases, news articles or download our press kit.
Learn More →
Contact Us
Speak to a member of our team to learn more about EMARKETER.
Contact Us →
EMARKETER
Already have a subscription?Sign In

Access All Charts and Data

Transparently sourced data in visual form, perfect for legitimizing your strategic ideas and thought leadership via internal and external presentations.

Lock icon
Lock icon

Access All Charts and Data

Transparently sourced data in visual form, perfect for legitimizing your strategic ideas and thought leadership via internal and external presentations.

January 2, 2025

Mounjaro and Zepbound Are Expected to See the Most New Sales of Any Prescription Drug in 2025

Mounjaro and Zepbound Are Expected to See the Most New Sales of Any Prescription Drug in 2025

Featured In

GLP-1 boom makes Eli Lilly the first $1 trillion pharma company

Chart Title

Mounjaro and Zepbound Are Expected to See the Most New Sales of Any Prescription Drug in 2025

Publication Date

January 2, 2025

Sources

Source information is only available to PRO subscribers.

Featured In

GLP-1 boom makes Eli Lilly the first $1 trillion pharma company
Topics
Prescription & OTC Drugs
Worldwide
EMARKETER

Coverage Areas →

Coverage Areas →

Advertising & Marketing

Health

Ecommerce & Retail

Technology

Financial Services

More Topics

Geographies

EMARKETER

Media Services

Free Content

Contact Us →

Worldwide HQ

685 Third Avenue21st FloorNew York, NY 100171-800-405-0844

Sales Inquiries

1-800-405-0844[email protected]

* Copyright © 2026 
EMARKETER Inc. All Rights Reserved.
Privacy PolicyYour Privacy ChoicesTerms of ServiceSitemap
Mounjaro and Zepbound Are Expected to See the Most New Sales of Any Prescription Drug in 2025 | EMARKETER